PL2115477T3 - Zastosowanie IGFBP-7 do oceny niewydolności serca - Google Patents
Zastosowanie IGFBP-7 do oceny niewydolności sercaInfo
- Publication number
- PL2115477T3 PL2115477T3 PL08707286T PL08707286T PL2115477T3 PL 2115477 T3 PL2115477 T3 PL 2115477T3 PL 08707286 T PL08707286 T PL 08707286T PL 08707286 T PL08707286 T PL 08707286T PL 2115477 T3 PL2115477 T3 PL 2115477T3
- Authority
- PL
- Poland
- Prior art keywords
- igfbp
- assessment
- heart failure
- heart
- failure
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07001582 | 2007-01-25 | ||
| EP08707286.4A EP2115477B1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
| PCT/EP2008/000576 WO2008089994A1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2115477T3 true PL2115477T3 (pl) | 2015-12-31 |
Family
ID=37810309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08707286T PL2115477T3 (pl) | 2007-01-25 | 2008-01-25 | Zastosowanie IGFBP-7 do oceny niewydolności serca |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20100285491A1 (pl) |
| EP (2) | EP2498095A3 (pl) |
| JP (1) | JP2010517023A (pl) |
| CN (2) | CN101636656A (pl) |
| CA (1) | CA2671298C (pl) |
| DK (1) | DK2115477T3 (pl) |
| ES (1) | ES2548009T3 (pl) |
| HU (1) | HUE025408T2 (pl) |
| PL (1) | PL2115477T3 (pl) |
| WO (1) | WO2008089994A1 (pl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2115477T3 (en) * | 2007-01-25 | 2015-08-10 | Hoffmann La Roche | USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE |
| WO2010096713A2 (en) * | 2009-02-20 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the diagnosis of age-associated vascular disorders |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
| JP5775874B2 (ja) * | 2009-08-28 | 2015-09-09 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| ES2592386T3 (es) * | 2009-12-20 | 2016-11-29 | Astute Medical, Inc. | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| PT2666872T (pt) * | 2010-02-05 | 2016-07-08 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| CN103080746B (zh) * | 2010-08-26 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
| FI20115367A0 (fi) * | 2011-04-15 | 2011-04-15 | Hytest Oy | Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| ES2595028T3 (es) | 2011-10-17 | 2016-12-27 | F. Hoffmann-La Roche Ag | Diagnóstico basado en Troponina y BNP de pacientes en riesgo y causa de ictus |
| ES2933570T3 (es) | 2011-12-08 | 2023-02-10 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y el pronóstico de una lesión renal y de una insuficiencia renal |
| WO2014023820A1 (en) | 2012-08-09 | 2014-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic of heart failure |
| EP4075143A1 (en) * | 2012-09-12 | 2022-10-19 | Roche Diagnostics GmbH | Identification of patients with abnormal fractional shortening |
| EP2730923A1 (en) * | 2012-11-09 | 2014-05-14 | Roche Diagniostics GmbH | NTproBNP and cTnT based therapy guidance in heart failure |
| CN104838271B (zh) * | 2012-12-04 | 2018-07-03 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
| EP3734280B8 (en) | 2013-01-17 | 2022-08-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| SI3004891T1 (sl) * | 2013-06-06 | 2019-08-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Biološki kazalnik za rehospitalizacijo po srčnem popuščanju |
| EP2843414B1 (en) * | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
| CN105793439B (zh) * | 2013-11-06 | 2020-09-04 | 阿斯图特医药公司 | 以生物样品进行的针对igfbp7的具有改进的性能的测定 |
| US10300108B2 (en) | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| EP3470848A3 (en) * | 2014-01-28 | 2019-05-22 | Roche Diagnostics GmbH | Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides |
| ES2676553T3 (es) * | 2014-03-26 | 2018-07-20 | F. Hoffmann-La Roche Ag | IGFBP7 para el diagnóstico de la disfunción diastólica |
| CN103926401A (zh) * | 2014-03-31 | 2014-07-16 | 瑞莱生物科技（江苏）有限公司 | 一种快速定量检测igfbp-7和timp-2的免疫荧光试纸条及其制备方法 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| ES2708325T5 (es) * | 2014-10-29 | 2023-02-17 | Hoffmann La Roche | Biomarcadores para la predicción del riesgo de progresión de insuficiencia cardiaca crónica y de la mortalidad |
| CN104408717A (zh) * | 2014-11-24 | 2015-03-11 | 北京航空航天大学 | 一种基于着色分离的病理图像颜色质量综合评价方法 |
| EP3281011B1 (en) | 2015-04-09 | 2024-06-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| BR112018015532A2 (pt) | 2016-02-29 | 2018-12-26 | Hoffmann La Roche | métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia |
| AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| ES2823124T3 (es) | 2016-06-17 | 2021-05-06 | Hoffmann La Roche | Angiopoyetina-2 (Ang-2) circulante para la predicción de recidiva de fibrilación auricular |
| US10865412B2 (en) * | 2016-11-04 | 2020-12-15 | Ottawa Heart Institute Research | Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases |
| WO2019115620A1 (en) | 2017-12-13 | 2019-06-20 | Roche Diagnostics Gmbh | Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke |
| JP2021532378A (ja) | 2018-07-20 | 2021-11-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ｉｇｆｂｐ−７に基づく妊娠高血圧腎症の予測 |
| KR20210044216A (ko) | 2018-08-10 | 2021-04-22 | 에프. 호프만-라 로슈 아게 | 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2) |
| EP3837549A1 (en) | 2018-08-16 | 2021-06-23 | Roche Diagnostics GmbH | Circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy |
| JP7333384B2 (ja) | 2018-08-22 | 2023-08-24 | エフ． ホフマン－ラ ロシュ アーゲー | 心房細動の評価における循環ｓｐｏｎ－１（スポンジン－１） |
| JP7451499B2 (ja) | 2018-08-24 | 2024-03-18 | エフ． ホフマン－ラ ロシュ アーゲー | 心房細動の判定および脳卒中の予測のための循環ｆｇｆｂｐ－１（線維芽細胞成長因子結合タンパク質１） |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| WO2020202241A1 (ja) * | 2019-03-29 | 2020-10-08 | 栄研化学株式会社 | 動脈硬化及び動脈硬化関連疾患マーカー |
| CN113939741A (zh) | 2019-05-23 | 2022-01-14 | 豪夫迈·罗氏有限公司 | HFpEF的IGFBP7比率 |
| JP2023537749A (ja) | 2020-08-14 | 2023-09-05 | エフ． ホフマン－ラ ロシュ アーゲー | 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７ |
| WO2023175152A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174A (en) | 1849-03-13 | Improvement in balances for weighing | ||
| US686A (en) | 1838-04-13 | Machine foe faking- and goring | ||
| US6333397B1 (en) | 1989-04-25 | 2001-12-25 | Roche Diagnostics Gmbh | Monoclonal antibodies to troponin T and their production |
| DE3922873A1 (de) | 1989-04-25 | 1990-10-31 | Boehringer Mannheim Gmbh | Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen |
| JPH07132095A (ja) | 1993-06-11 | 1995-05-23 | Nawata Arata | Ｄｎａおよびそのコードする蛋白質 |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6174686B1 (en) * | 1995-04-18 | 2001-01-16 | Biosite Diagnostics, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
| US6709855B1 (en) * | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
| EP1151101A4 (en) | 1998-12-18 | 2002-10-09 | Human Genome Sciences Inc | PROSTACYCLINE STIMULANT FACTOR-2 |
| WO2000035473A2 (en) * | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
| CN101046478B (zh) * | 1999-01-29 | 2013-04-03 | 罗赫诊断器材股份有限公司 | 鉴定样品中的n-末端前bnp的方法 |
| EP1295939A4 (en) | 2000-06-15 | 2005-02-02 | Kyowa Hakko Kogyo Kk | INSULIN SIMILAR GROWTH FACTOR BINDING PROTEIN |
| US20030119009A1 (en) * | 2001-02-23 | 2003-06-26 | Stuart Susan G. | Genes regulated by MYCN activation |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| AU2002305394A1 (en) * | 2001-05-04 | 2002-11-18 | Biosite, Inc. | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
| AU2003301843A1 (en) | 2002-05-17 | 2004-06-07 | Human Genome Sciences, Inc. | 157 human secreted proteins |
| GB0216191D0 (en) * | 2002-07-11 | 2002-08-21 | Univ Leicester | Plasma urotensin in human heart failure |
| ES2372282T3 (es) | 2003-05-12 | 2012-01-18 | F. Hoffmann-La Roche Ag | Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 38-43. |
| GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
| US20060003338A1 (en) | 2004-06-30 | 2006-01-05 | Deng David X | System and methods for the management and treatment of vascular graft disease |
| US7659091B2 (en) * | 2004-09-21 | 2010-02-09 | Nourheart, Inc. | Diagnostic marker |
| ITVI20050059A1 (it) | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| EP1875248A2 (en) * | 2005-03-29 | 2008-01-09 | Inverness Medical Switzerland GmbH | Device and method of monitoring a patient |
| DE102005014752A1 (de) * | 2005-03-31 | 2006-11-23 | Johannes-Gutenberg-Universität Mainz | Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen |
| EP1722232A1 (en) * | 2005-05-09 | 2006-11-15 | F.Hoffmann-La Roche Ag | Devices and methods for diagnosing or predicting early stage cardiac dysfunctions |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| EP2095107B1 (en) * | 2006-11-14 | 2014-07-02 | Alere San Diego, Inc. | Methods for risk assignment |
| DK2115477T3 (en) * | 2007-01-25 | 2015-08-10 | Hoffmann La Roche | USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE |
| EP1967853B1 (en) * | 2007-03-06 | 2010-01-27 | Roche Diagnostics GmbH | Use of Nogo-C in the assessment of heart failure |
| JP5081930B2 (ja) * | 2007-03-08 | 2012-11-28 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるｓｌｉｍ−１の使用 |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
-
2008
- 2008-01-25 DK DK08707286.4T patent/DK2115477T3/en active
- 2008-01-25 CA CA2671298A patent/CA2671298C/en active Active
- 2008-01-25 EP EP12156343A patent/EP2498095A3/en not_active Withdrawn
- 2008-01-25 CN CN200880003100A patent/CN101636656A/zh active Pending
- 2008-01-25 WO PCT/EP2008/000576 patent/WO2008089994A1/en active Application Filing
- 2008-01-25 HU HUE08707286A patent/HUE025408T2/hu unknown
- 2008-01-25 PL PL08707286T patent/PL2115477T3/pl unknown
- 2008-01-25 EP EP08707286.4A patent/EP2115477B1/en active Active
- 2008-01-25 JP JP2009546687A patent/JP2010517023A/ja active Pending
- 2008-01-25 ES ES08707286.4T patent/ES2548009T3/es active Active
- 2008-01-25 CN CN201610893998.1A patent/CN106908603B/zh active Active
-
2009
- 2009-07-16 US US12/504,208 patent/US20100285491A1/en not_active Abandoned
-
2014
- 2014-11-13 US US14/540,165 patent/US20150293122A1/en not_active Abandoned
-
2016
- 2016-10-05 US US15/285,685 patent/US10488422B2/en active Active
-
2019
- 2019-10-10 US US16/598,361 patent/US10996229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2115477T3 (en) | 2015-08-10 |
| US20170016918A1 (en) | 2017-01-19 |
| EP2115477B1 (en) | 2015-06-24 |
| JP2010517023A (ja) | 2010-05-20 |
| WO2008089994A1 (en) | 2008-07-31 |
| US20100285491A1 (en) | 2010-11-11 |
| US10488422B2 (en) | 2019-11-26 |
| CA2671298A1 (en) | 2008-07-31 |
| US10996229B2 (en) | 2021-05-04 |
| EP2498095A2 (en) | 2012-09-12 |
| HUE025408T2 (hu) | 2016-02-29 |
| EP2115477A1 (en) | 2009-11-11 |
| US20200064359A1 (en) | 2020-02-27 |
| CA2671298C (en) | 2020-07-28 |
| EP2498095A3 (en) | 2012-11-28 |
| ES2548009T3 (es) | 2015-10-13 |
| CN101636656A (zh) | 2010-01-27 |
| WO2008089994A8 (en) | 2009-05-22 |
| CN106908603B (zh) | 2019-04-02 |
| US20150293122A1 (en) | 2015-10-15 |
| CN106908603A (zh) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2115477T3 (pl) | Zastosowanie IGFBP-7 do oceny niewydolności serca | |
| HK1224375A1 (zh) | 在評價心力衰竭中的用途 | |
| ZA201007523B (en) | Heart age assessment | |
| IL191773A0 (en) | Cardiac mechanical assessment using ultrasound | |
| IL212451A0 (en) | Adsorptive structures and the use thereof | |
| GB0701426D0 (en) | Compounds and their use | |
| HK1139733A1 (en) | Diagnosis and risk stratification using nt-proet-1 nt-proet-1 | |
| GB0818241D0 (en) | Compounds and their use | |
| PL2036882T3 (pl) | Związki o jonach obojnaczych i ich zastosowanie | |
| GB0803018D0 (en) | Therapeutic compounds and their use | |
| IL208081A0 (en) | Amido - thiophene compounds and their use | |
| ZA201007395B (en) | Aryl-quinolyl compounds and their use | |
| EP2307052A4 (en) | ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE | |
| PL2344449T3 (pl) | Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie | |
| GB0817208D0 (en) | Therapeutic apsap compounds and their use | |
| EP2241436A4 (en) | ADHESIVE-FREE FLEXIBLE LAMINATE | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE | |
| SI2182954T1 (sl) | Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze | |
| GB0708507D0 (en) | Substituted phosphonates and their use | |
| GB0801319D0 (en) | Compounds and their use | |
| GB0703514D0 (en) | Use of riboflavin | |
| EP2252305A4 (en) | OMENTUM AND ITS USE | |
| GB0802128D0 (en) | Therapeutic compounds and their use | |
| GB0815134D0 (en) | Therapeutic compounds and their use | |
| PL383157A1 (pl) | Sposób otrzymywania monochloropropandioli i dichloropropanoli |